KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Receivables (2016)

Novavax has reported Change in Receivables over the past 7 years, most recently at -$1.7 million for Q3 2016.

  • Quarterly results put Change in Receivables at -$1.7 million for Q3 2016, down 243.2% from a year ago — trailing twelve months through Sep 2016 was -$5.7 million (down 55.73% YoY), and the annual figure for FY2021 was -$144.4 million, up 41.25%.
  • Change in Receivables for Q3 2016 was -$1.7 million at Novavax, down from -$26000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for NVAX hit a ceiling of $2.8 million in Q4 2014 and a floor of -$6.0 million in Q2 2015.
  • Median Change in Receivables over the past 5 years was -$240000.0 (2012), compared with a mean of -$464894.7.
  • Biggest five-year swings in Change in Receivables: skyrocketed 1661.25% in 2014 and later plummeted 2569.23% in 2016.
  • Novavax's Change in Receivables stood at -$1.5 million in 2012, then soared by 110.97% to $160000.0 in 2013, then skyrocketed by 1661.25% to $2.8 million in 2014, then plummeted by 171.43% to -$2.0 million in 2015, then increased by 14.75% to -$1.7 million in 2016.
  • The last three reported values for Change in Receivables were -$1.7 million (Q3 2016), -$26000.0 (Q2 2016), and -$1.9 million (Q1 2016) per Business Quant data.